177 related articles for article (PubMed ID: 30134191)
1. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
[TBL] [Abstract][Full Text] [Related]
2. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
Hong CR; Wilson WR; Hicks KO
Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
[TBL] [Abstract][Full Text] [Related]
3. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
Meng F; Evans JW; Bhupathi D; Banica M; Lan L; Lorente G; Duan JX; Cai X; Mowday AM; Guise CP; Maroz A; Anderson RF; Patterson AV; Stachelek GC; Glazer PM; Matteucci MD; Hart CP
Mol Cancer Ther; 2012 Mar; 11(3):740-51. PubMed ID: 22147748
[TBL] [Abstract][Full Text] [Related]
4. Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
Hong CR; Mehta SY; Liyanage HDS; McManaway SP; Lee HH; Jaiswal JK; Bogle G; Tercel M; Pruijn FB; Wilson WR; Hicks KO
Cancer Chemother Pharmacol; 2021 Oct; 88(4):673-687. PubMed ID: 34245333
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
Takakusagi Y; Kishimoto S; Naz S; Matsumoto S; Saito K; Hart CP; Mitchell JB; Krishna MC
Antioxid Redox Signal; 2018 Jan; 28(2):131-140. PubMed ID: 28741367
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
[No Abstract] [Full Text] [Related]
8. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
[TBL] [Abstract][Full Text] [Related]
9. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
[TBL] [Abstract][Full Text] [Related]
11. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
[TBL] [Abstract][Full Text] [Related]
14. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
15. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.
Liapis V; Labrinidis A; Zinonos I; Hay S; Ponomarev V; Panagopoulos V; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
Cancer Lett; 2015 Feb; 357(1):160-169. PubMed ID: 25444931
[TBL] [Abstract][Full Text] [Related]
17. Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer.
Anderson RF; Li D; Hunter FW
Free Radic Biol Med; 2017 Dec; 113():564-570. PubMed ID: 29111232
[TBL] [Abstract][Full Text] [Related]
18. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
20. Evofosfamide, a new horizon in the treatment of pancreatic cancer.
Pourmorteza M; Rahman ZU; Young M
Anticancer Drugs; 2016 Sep; 27(8):723-5. PubMed ID: 27232101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
